Recruiting
Phase 3

Magnesium with Prochlorperazine

Sponsor:

Wake Forest University Health Sciences

Code:

NCT06904287

Conditions

Migraine

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Magnesium

Placebo

Study Details

Brief summary:

The purpose of this research study is to find out if using magnesium in addition to prochlorperazine will help reduce your migraine pain.

Conditions

Migraine

Study ID

NCT06904287

Start date

Dec 16, 2025

Status verified date

Jan, 2026

Completion date

Jun, 2027

Anticipated

Primary completion date

Jun, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Age ≥ 18 years or older
  • Able to provide informed consent
  • English speaking
  • Primary diagnosis of migraine. Patient with a previous diagnosis of migraine, who experience headaches with typical migraine features (e.g at least 2-3 of the following: recurrent, unilateral, pounding or throbbing in nature, associated with nausea), AND with a clinical exclusion of migraine mimics

Exclusion Criteria:

  • Pregnancy defined as a positive urine HCG
  • Allergy or sensitivity to study drug
  • Stated history of renal insufficiency
  • Documented history of myasthenia gravis
  • Consumption of study drug within 48 hours prior to enrollment
  • Previously enrolled in this trial during a different patient encounter

Study Design

Enrollment

100 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Study Drug

Prochlorperazine 10 mg followed by Magnesium 2 g

active comparator: Control Arm

Prochlorperazine 10 mg followed by placebo

Interventions

Magnesium

Prochlorperazine 10 mg administered as an intravenous push over 2 minutes followed by magnesium 2 g administered as an intravenous bolus over a period of 20 minutes

Placebo

Prochlorperazine 10 mg administered as an intravenous push over 2 minutes followed by placebo (normal saline)

Primary outcome measure

  • Mean change in pain - baseline to 30 minutes [ Time Frame: Baseline to 30 minutes after initiation of infusion ]

Central Contacts and Locations

Central contacts

Ryan McKillip, MD

708-684-6230ryan.mckillip@aah.org

Marc McDowell, PharmD

708-684-1078marc.mcdowell@aah.org

Locations

Advocate Christ Medical Center Emergency Department

Recruiting

Oak Lawn, Illinois, United States, 60453

Contacts

Samar Ashrafi, PharmD

708-684-7895samar.ashrafi@aah.org

More Information

Sponsor

Wake Forest University Health Sciences

Last update posted

Jan 22, 2026

Last verified

Jan, 2026

Keywords

  • Migraine
  • Magnesium

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Wake Forest University Health Sciences on 2026-01-22.